Journal of Infection and Chemotherapy最新文献

{"title":"Increase in the age of onset of pediatric acute otitis media after the Covid-19 pandemic: A study at a primary emergency medical center","authors":"Shingo Ishimori ,&nbsp;Akihiro Nishimura ,&nbsp;Akihiro Tamura ,&nbsp;Kazumichi Fujioka ,&nbsp;Kandai Nozu ,&nbsp;Masaaki Kugo","doi":"10.1016/j.jiac.2025.102875","DOIUrl":"10.1016/j.jiac.2025.102875","url":null,"abstract":"<div><h3>Background</h3><div>During the coronavirus disease 2019 (Covid-19) pandemic, rigorous infection control measures led to a decrease in the incidence of various infectious diseases. In this study, we investigated the clinical characteristics of acute otitis media (AOM) children during the post-Covid-19 period at a primary emergency medical center.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed children with AOM who visited Kobe Children's Primary Emergency Medical Center between April 2017 and March 2024. Patients with AOM or suppurative otitis media were included. We defined each fiscal year (FY) as the period from April to the following March. We defined the “pre-Covid-19 period” as FY2017–2019, the “Covid-19 period” as FY2020–2022, and “post-Covid-19 period” as FY2023.</div></div><div><h3>Results</h3><div>A total of 2078 AOM cases were included. The mean age at presentation was 3.5 years. A significant difference in age was present across the three FY time periods. The age during the post-Covid-19 period was significantly higher than that during the pre-Covid-19 period using the pairwise comparisons (p &lt; 0.05). In a multivariate analysis between the pre-Covid-19 and post-Covid-19 periods, age at onset (95 % confidence intervals: 1.02–1.11) was the only independent factor associated with the post-Covid-19 period. Between the Covid-19 and post-Covid-19 periods, age at onset (95 % confidence intervals: 1.02–1.15) and body temperature (95 % confidence intervals: 1.05–1.40) were significantly associated with the post-Covid-19 period.</div></div><div><h3>Conclusions</h3><div>A multifactorial effect may have contributed to the increase in age at the onset of AOM during the post-Covid-19 period compared with the other study periods.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102875"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145587665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The current status of neonatal echovirus 11 infections in Japan: A comparison to the global situation","authors":"Takanori Funaki ,&nbsp;Kensuke Shoji","doi":"10.1016/j.jiac.2025.102879","DOIUrl":"10.1016/j.jiac.2025.102879","url":null,"abstract":"<div><div>Enteroviruses (EVs) are one of the most common causes of severe neonatal infections. The spectrum of diseases varies with age, sex, and immune status. As molecular methods have evolved, several new EVs have been identified, bringing the total number of serotypes to over 100. Since 2022, the World Health Organization has published Disease Outbreak News on echovirus 11 (E11) infections due to an increase in severe neonatal E11 infections in several European countries. In Japan, several life-threatening neonatal cases were also reported in the summer of 2024. Clinical characteristics of severe cases include rapid clinical deterioration with multiorgan failure, hemophagocytic lymphohistiocytosis-like inflammatory features, and a high mortality rate. Male infants are likely to experience severe outcomes, specifically in neonates, onset soon after birth, and possible maternal peripartum infection. Meanwhile, older infants with aseptic meningitis often show mild, self-limited disease. Genomic characteristics indicate that a new recombinant genotype D5 is the predominant circulating E11 lineage worldwide. Recent severe neonatal cases linked to a closely related genetic variant that may have increased pathogenicity. This evidence suggests both viral evolution and immature neonatal immunity may contribute to the disease severity. Given the newly initiated nationwide surveillance in Japan, enhanced EV surveillance and rapid genomic characterization are crucial for early identification of severe E11 infection in neonates.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102879"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145668452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of Baloxavir marboxil versus oseltamivir in outpatients aged 1 to under 5 years in China: a multicenter, retrospective cohort study","authors":"Chengyu Li ,&nbsp;Yanwu Zhang ,&nbsp;Ming Yang ,&nbsp;Xiao Liu ,&nbsp;Shuhui Tian ,&nbsp;Zoe Fu ,&nbsp;Alastair Mah ,&nbsp;Hongjie Yu ,&nbsp;Qianli Wang ,&nbsp;Helen Zhang","doi":"10.1016/j.jiac.2025.102874","DOIUrl":"10.1016/j.jiac.2025.102874","url":null,"abstract":"<div><h3>Objectives</h3><div>Baloxavir marboxil (BXM) is a novel single-dose antiviral agent. The benefit and risk assessment of BXM use in children under 5 years of age remains scarce in China. We aimed to investigate the real-world effectiveness of BXM in this vulnerable population in China.</div></div><div><h3>Study design</h3><div>This retrospective study analyzed real-world outpatient data from 13 United Family Healthcare hospitals and clinics in China (Oct 2023–Apr 2024), identifying 1-&lt;5 years old lab-confirmed influenza patients treated with BXM or Oseltamivir (OSV). Patients admitted within 14 days post-initial visit for the same condition were evaluated. Influenza-related return visits, symptoms and signs and complications were compared between BXM and OSV groups at 3, 7, and 14 days post-initial visit. Propensity score matching (PSM) was used to reduce bias and balance groups for analysis.</div></div><div><h3>Results</h3><div>We identified 1473 influenza infected outpatients for analysis, 359 patients received BXM treatment, while 1114 were treated with OSV. The proportion of hospitalization within 14 days were comparable between the BXM group (0.8 %, 3/359) and the OSV (1.0 %, 11/1114). Return visit were consistently higher in the OSV group across all time points, while fewer persistent symptoms and signs (within 3, 7, and 14 days) were observed in the BXM group; after PSM, the BXM group demonstrated consistently slightly fewer return visit for the same illness across all time points compared to the OSV group, none of these differences reached statistical significance.</div></div><div><h3>Conclusion</h3><div>BXM, the single-dose oral regimen, has demonstrated comparable effectiveness to OSV in terms of influenza-related return visits and hospitalization rates.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102874"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145581958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia","authors":"Yuki Mizukami ,&nbsp;Mishu Takahashi ,&nbsp;Kenta Suzuki ,&nbsp;Shaoqing Duan ,&nbsp;Shintaro Ikegami ,&nbsp;Takuma Muraishi ,&nbsp;Natsuki Satake ,&nbsp;Yuko Okamoto ,&nbsp;Yuki Igarashi ,&nbsp;Yuki Enoki ,&nbsp;Kazuaki Taguchi ,&nbsp;Kazuaki Matsumoto","doi":"10.1016/j.jiac.2025.102889","DOIUrl":"10.1016/j.jiac.2025.102889","url":null,"abstract":"<div><h3>Introduction</h3><div>Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC_i), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC_i-based PK/PD analysis in the lung epithelial lining fluid (ELF).</div></div><div><h3>Methods</h3><div><em>In vitro</em> pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing <em>Klebsiella pneumoniae</em> strains. <em>In vivo</em> PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC_i-based PK/PD analysis was conducted.</div></div><div><h3>Results</h3><div><em>In vitro</em>, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12–4.30 log₁₀ CFU/lung, while the combination therapy reduced bacterial counts by −5.93 to −0.234 log₁₀ CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC_i (T &gt; MIC_i) was highly correlated with bacterial reduction. The target T &gt; MIC_i for maximal effect was estimated to be 29.3 %.</div></div><div><h3>Conclusions</h3><div>These findings support the utility of MIC_i-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102889"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145723089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine-related beliefs and preventive behavior among Japanese travelers staying at a budget guesthouse in New Delhi, India: travel vaccinations after the COVID-19 pandemic","authors":"Michiyo Yamakawa ,&nbsp;Yuko Tanaka ,&nbsp;Akiko Tokinobu ,&nbsp;Toshihide Tsuda","doi":"10.1016/j.jiac.2025.102894","DOIUrl":"10.1016/j.jiac.2025.102894","url":null,"abstract":"<div><h3>Background</h3><div>With a rapid recovery in international travel after the COVID-19 pandemic, improving vaccination uptake among travelers is critical to preventing the cross-border spread of pathogens. We examined the associations between vaccine-related beliefs and vaccination behavior among Japanese travelers staying at a budget guesthouse in New Delhi, India.</div></div><div><h3>Methods</h3><div>Japanese travelers aged 16–75 years who stayed at a budget guesthouse in Paharganj, New Delhi were targeted (n = 1493). Cross-sectional surveys were conducted from December 14, 2022, to March 28, 2024, and from August 1 to October 7, 2024, using a web-based questionnaire. Vaccination behavior was defined as the primary outcome from whether individuals had gotten any vaccines for their travel. We examined the associations of four vaccine-related belief items (each on a 5-point scale for confidence, barriers, trust, and natural immunity) with vaccination behavior.</div></div><div><h3>Results</h3><div>In total (n = 853), 447 participants (52.4 %) had not received any vaccines for international travel. After adjusting for all potential confounders, 1-point increases in vaccine confidence and medical trust were positively associated with vaccination behavior, i.e., ORs (95 % CIs) of 1.60 (1.34, 1.92) and 1.52 (1.35, 1.73), respectively. In contrast, a 1-point increase in belief in natural immunity was negatively associated with vaccination behavior.</div></div><div><h3>Conclusions</h3><div>Addressing vaccine confidence, medical trust, and beliefs in natural immunity would be beneficial to promoting travel vaccinations among Japanese travelers staying at a budget guesthouse in New Delhi, India.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102894"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first pediatric case successfully treated with cefiderocol for IMP-type carbapenemase-producing Enterobacterales bacteremia","authors":"Haruna Mori ,&nbsp;Yuto Otsubo ,&nbsp;Meiwa Shibata ,&nbsp;Kyogo Suzuki ,&nbsp;Yuho Horikoshi","doi":"10.1016/j.jiac.2025.102899","DOIUrl":"10.1016/j.jiac.2025.102899","url":null,"abstract":"<div><div>Cefiderocol, a novel β-lactam antibiotic, exhibits potent activity against carbapenemase-producing Enterobacterales (CPE). While its clinical efficacy has been reported for infections caused by KPC-type CPE and <em>Stenotrophomonas maltophilia</em>, evidence regarding its effectiveness against IMP-type CPE remains primarily derived from in vitro studies, with limited clinical data available. This is the first pediatric case successfully treated with cefiderocol for IMP-type CPE bacteremia. He was a 6-year-old boy with inherited glycosylphosphatidylinositol deficiency and acute lymphoblastic leukemia undergoing chemotherapy. He developed bacteremia that blood culture multiplex PCR identified <em>Klebsiella pneumoniae</em> with IMP gene. The combination therapy of cefiderocol 60mg/kg/dose every 8 hours and gentamicin 5mg/kg/dose once daily sterilized blood culture, and subsequent monotherapy with cefiderocol was continued for a total of 14 days. Additional molecular test in the strain detected IMP-1 carbapenemase, SHV extended spectrum β-lactamase and EBC-type AmpC β-lactamase. Cefiderocol was susceptible at minimum inhibitory concentration 0.5μg/mL. Further study is needed for cefiderocol treatment for IMP-type CPE infection in children.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102899"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma","authors":"Aika Kitamura ,&nbsp;Shinya Fujita ,&nbsp;Yuki Isono ,&nbsp;Tomoka Nakano ,&nbsp;Takumi Morino ,&nbsp;Kiho Tozuka ,&nbsp;Himari Kudo ,&nbsp;Ryohei Abe ,&nbsp;Sumiko Kohashi ,&nbsp;Takaaki Toyama","doi":"10.1016/j.jiac.2025.102851","DOIUrl":"10.1016/j.jiac.2025.102851","url":null,"abstract":"<div><div>Elranatamab (ELRA), a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, is effective in patients with triple-class refractory multiple myeloma (TCRMM). However, its T cell–engaging mechanism can induce profound immunosuppression. We retrospectively evaluated infectious complications, including cytomegalovirus (CMV) reactivation, in five TCRMM patients treated with ELRA at our institution. The median age was 77 years, and all patients experienced grade ≥3 lymphopenia. Four (80 %) developed CMV reactivation within 50 days of treatment initiation—markedly higher than the 1.8–5.7 % reported in clinical trials. All reactivation cases were detected by PCR (&gt;500 IU/mL) and managed pre-emptively with valganciclovir; no CMV disease occurred. Absolute lymphocyte counts declined rapidly by day 8 (mean 287/μL) and remained suppressed for over two months in most patients. CD4⁺ T-cell counts were persistently low (22–75/μL) in four of five patients. Neutropenia was transient and inconsistent; bacterial infections occurred in two patients, and no fungal infections were observed. These real-world data suggest that treatment with ELRA in older, transplant-ineligible patients may be associated with a high risk of CMV reactivation than previously appreciated, likely driven by prolonged lymphopenia with a potential contribution from hypogammaglobulinemia. Our results underscore the importance of routine CMV monitoring and lymphocyte profiling during ELRA therapy. Further prospective studies are warranted to optimize infection surveillance and prophylactic strategies in this population. To our knowledge, this is the first case series from Japan to describe infectious complications of ELRA in routine practice, providing important real-world evidence for clinicians.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102851"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145477017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change of pediatric quality of life following inactivated influenza vaccination using EuroQol-5 dimensions-youth","authors":"Rika Suzuki,&nbsp;Takahiro Mori,&nbsp;Soshi Hachisuka,&nbsp;Tenshin Okubo,&nbsp;Naohiro Yamamoto,&nbsp;Hiroki Nishikawa,&nbsp;Masayuki Onaka,&nbsp;Sayaka Yoshida,&nbsp;Taito Kitano","doi":"10.1016/j.jiac.2025.102890","DOIUrl":"10.1016/j.jiac.2025.102890","url":null,"abstract":"<div><h3>Background</h3><div>Measuring vaccination's impact on health-related quality of life (HRQL) is fundamental for cost-effectiveness analyses and health technology assessments, yet pediatric data remain limited. This study measured HRQL impact from reactogenicity symptoms following inactivated influenza vaccination in Japanese children.</div></div><div><h3>Methods</h3><div>This prospective study used proxy-reported EuroQol-5 dimension youth (EQ-5D-Y) questionnaires to evaluate HRQL daily from pre-vaccination to 7 d post-vaccination per dose in children aged 4–15 years during the 2024–2025 influenza season. Quality-adjusted life day (QALD) loss per dose for the EQ-5D-Y was calculated to quantify the impact of reactogenicity after receiving the inactivated influenza vaccine. The severity of reactogenicity symptoms was classified using the adverse events following immunization (AEFI) grading scale (grades 0–4).</div></div><div><h3>Results</h3><div>Overall, 218 children received 381 doses of inactivated influenza vaccination. QALD loss (positive score indicates worse post-vaccination states) was −0.032 (first dose) and 0.012 (second dose). The mean QALD loss for first dose recipients was −0.038 (grade 0–1 AEFI) and −0.009 (grade 2–4 AEFI); second dose values were −0.004 (grade 0–1) and 0.085 (grade 2–4).</div></div><div><h3>Conclusion</h3><div>QALD loss within 1 week post-vaccination (either first or second dose) was negligible, confirming inactivated influenza vaccine safety in this population.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102890"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145742289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing the daily infusion time of peripheral parenteral nutrition to prevent bloodstream infection in hospitalized patients","authors":"Masafumi Shimoda,&nbsp;Yoshiaki Tanaka,&nbsp;Hiroyuki Kokutou,&nbsp;Takashi Yoshiyama,&nbsp;Kozo Morimoto,&nbsp;Kozo Yoshimori,&nbsp;Shoji Kudoh","doi":"10.1016/j.jiac.2025.102884","DOIUrl":"10.1016/j.jiac.2025.102884","url":null,"abstract":"<div><h3>Introduction</h3><div>Peripheral parenteral nutrition (PPN), administered via a peripheral intravenous catheter (PVC), can occasionally lead to bloodstream infections (BSIs). We previously reported that a prolonged daily infusion time of PPN and all intravenous fluids were risk factors for BSI development. In response, our institution implemented a recommendation to limit the average daily infusion time of PPN to &lt;12 h and that of all intravenous fluids to &lt;18 h. The aim of this study was to investigate whether the incidence of BSI in patients receiving PPN decreased following the implementation of these recommendations.</div></div><div><h3>Methods</h3><div>We retrospectively collected data from 714 patients who underwent PPN therapy via PVC at Fukujuji Hospital from August 2022 to July 2025. We compared the incidence of BSI during PPN therapy between the preintervention and postintervention periods.</div></div><div><h3>Results</h3><div>Among the 714 patients, 507 were in the preintervention group, and 207 were in the postintervention group. The proportion of patients who developed BSIs was significantly lower in the postintervention group than in the preintervention group (n = 2 [1.0 %] vs. n = 27 [5.3 %], <em>p</em> = 0.006). The crude BSI incidence rate decreased from 3.59 to 0.73 per 1000 infusion days. A multivariable Poisson regression model revealed that the postintervention period was associated with a significantly lower BSI incidence rate (adjusted incidence rate ratio: 0.190; 95 % confidence interval: 0.045–0.804; <em>p</em> = 0.024), corresponding to an approximately 81 % reduction in BSI incidence.</div></div><div><h3>Conclusion</h3><div>Shortening the average daily infusion time of PPN and all intravenous fluids may help prevent the development of BSIs.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102884"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145682332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does having allergic diseases affect SARS-CoV-2 antibody responses to mRNA vaccination in adolescents?","authors":"Mayako Saito-Abe ,&nbsp;Kiwako Yamamoto-Hanada ,&nbsp;Tatsuki Fukuie ,&nbsp;Kensuke Shoji ,&nbsp;Yukihiro Ohya","doi":"10.1016/j.jiac.2025.102893","DOIUrl":"10.1016/j.jiac.2025.102893","url":null,"abstract":"<div><h3>Background</h3><div>Understanding factors influencing vaccine-induced immunity in adolescents is important for optimizing COVID-19 vaccination strategies. Allergic diseases have been hypothesized to alter immune responses through Th2-dominant inflammation, but data regarding their impact on SARS-CoV-2 mRNA vaccine antibody production remain limited in real-world adolescent populations. The purpose of this study is to identify factors affecting SARS-CoV-2 antibody titers after mRNA vaccination in a general population of 16- to 17-year-olds.</div></div><div><h3>Methods</h3><div>This study analyzed data from 233 participants in the T-CHILD Study, a Japanese general birth cohort, who received their 17-year medical checkup between July 2021 and October 2023. Individuals with a history of COVID-19 or serological evidence of prior infection (positive for both S- and N-antibodies) were excluded. Associations between SARS-CoV-2 S-antibody titers and vaccination history, allergic diseases, and other variables were examined.</div></div><div><h3>Results</h3><div>Multivariate analysis revealed that only a higher number of vaccine doses was independently associated with higher SARS-CoV-2 antibody titers. No significant associations were found between antibody titers and vaccine type, the interval since the last vaccination, allergic diseases such as asthma, atopic dermatitis (AD), or food allergy, or with total serum IgE levels.</div></div><div><h3>Conclusions</h3><div>These findings suggest that adolescents with mild allergic diseases can mount sufficient immune responses to SARS-CoV-2 mRNA vaccines, supporting the safety and efficacy of vaccination in this population. (230 words)</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"32 1","pages":"Article 102893"},"PeriodicalIF":1.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}